Renaissance Technologies LLC Has $5.04 Million Stake in Cronos Group Inc. $CRON

Renaissance Technologies LLC lifted its stake in Cronos Group Inc. (NASDAQ:CRON) by 8.9% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 2,009,549 shares of the company’s stock after acquiring an additional 164,500 shares during the period. Renaissance Technologies LLC owned 0.53% of Cronos Group worth $5,044,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Jones Financial Companies Lllp grew its holdings in Cronos Group by 291.6% during the first quarter. Jones Financial Companies Lllp now owns 65,099 shares of the company’s stock valued at $118,000 after purchasing an additional 48,476 shares during the last quarter. Goldman Sachs Group Inc. lifted its stake in shares of Cronos Group by 84.6% in the first quarter. Goldman Sachs Group Inc. now owns 1,076,405 shares of the company’s stock worth $1,948,000 after buying an additional 493,161 shares during the last quarter. Envestnet Asset Management Inc. bought a new stake in shares of Cronos Group during the 2nd quarter worth $36,000. Legal & General Group Plc boosted its holdings in shares of Cronos Group by 16.1% during the 2nd quarter. Legal & General Group Plc now owns 195,368 shares of the company’s stock worth $374,000 after buying an additional 27,111 shares during the period. Finally, Arrowstreet Capital Limited Partnership grew its stake in Cronos Group by 192.4% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 89,683 shares of the company’s stock valued at $171,000 after buying an additional 59,013 shares during the last quarter. Institutional investors own 8.71% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the stock. TD Securities restated a “buy” rating on shares of Cronos Group in a report on Tuesday, May 12th. Weiss Ratings reissued a “sell (d+)” rating on shares of Cronos Group in a research report on Friday, May 29th. Finally, Wall Street Zen raised Cronos Group from a “hold” rating to a “buy” rating in a report on Saturday, May 16th. Two research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $2.30.

More Cronos Group News

Here are the key news stories impacting Cronos Group this week:

• Positive Sentiment: Cronos reported record second-quarter organic revenue, gross profit and adjusted EBITDA. Organic, constant-currency revenue increased 51% year over year, while adjusted EBITDA reached $13.1 million. Cronos Group Reports 2026 Second Quarter Results
• Positive Sentiment: The company exceeded quarterly expectations, reporting earnings of approximately $0.03 to $0.09 per share versus a consensus estimate of $0.01. Revenue was $53.01 million, above the $44.20 million analyst forecast. Cronos Group Surpasses Q2 Earnings and Revenue Estimates
• Positive Sentiment: Growth was broad-based: Spinach maintained the No. 1 position in Canadian vapes and edibles, PEACE NATURALS continued its leading position in Israel, and demand in Germany helped drive record revenue outside Canada and Israel.
• Positive Sentiment: Cronos repurchased 12.3 million shares during the first half of 2026, reducing the share count and potentially supporting per-share results.
• Positive Sentiment: The planned acquisition of CanAdelaar is expected to close in the second half of 2026, potentially adding to Cronos’ growth and operating scale. Cronos CanAdelaar Acquisition and Q2 Adjusted EBITDA
• Neutral Sentiment: Despite the earnings beat, Cronos remained marginally unprofitable, with a negative net margin and negative return on equity. Investors will likely focus on whether the improved adjusted EBITDA converts into sustained net profitability.

Cronos Group Trading Up 12.9%

Shares of NASDAQ CRON opened at $3.07 on Friday. The firm has a market capitalization of $1.14 billion, a price-to-earnings ratio of 307.31 and a beta of 0.90. Cronos Group Inc. has a one year low of $2.14 and a one year high of $3.43. The business has a fifty day simple moving average of $2.77 and a 200 day simple moving average of $2.67.

Cronos Group (NASDAQ:CRON) last posted its quarterly earnings results on Monday, May 11th. The company reported $0.01 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.01. Cronos Group had a negative net margin of 1.14% and a negative return on equity of 1.26%. The firm had revenue of $45.21 million for the quarter, compared to the consensus estimate of $42.20 million. On average, research analysts anticipate that Cronos Group Inc. will post 0.07 earnings per share for the current fiscal year.

About Cronos Group

Cronos Group Inc is a Canadian cannabinoid company dedicated to the cultivation, production and distribution of cannabis and cannabidiol (CBD) products for both medical and adult-use markets. Headquartered in Toronto, Ontario, the company manages operations that span the full cannabis value chain, including breeding, greenhouse cultivation, extraction, product formulation and packaging. Cronos Group’s business model emphasizes innovation in product development and scalability in manufacturing to meet evolving regulatory and consumer demands.

The company’s branded portfolio includes Peace Naturals, which focuses on pharmaceutical-grade medical cannabis; Spinach, a line of adult-use cannabis oils and tinctures; and Cove, a range of wellness-oriented CBD offerings.